Observational studyFrontiers in immunology2026
Systemic lupus erythematosus-related mortality declined but disparities persisted in the United States: a nationwide multiple-cause-of-death analysis, 1999-2023.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) causes substantial premature mortality. Contemporary national data on long-term SLE-related mortality and its demographic and geographic disparities in the United States remain limited, particularly across the transition into the COVID-19 era. Methods: We conducted a nationwide observational study using the 1999-2023 CDC WONDER Multiple Cause of Death database. SLE-related mortality was defined as any death certificate mention of SLE (ICD-10 M32). An underlying-cause-only sensitivity analysis assessed trend robustness. Annual deaths and age-adjusted mortality rates (AAMRs) were examined overall and by sex, age, race, geography, and urbanization. Temporal trends were evaluated using joinpoint regression to estimate annual percent changes (APCs) and average annual percent changes (AAPCs). Pooled state-level AAMRs were compared between 2016-2019 and 2020-2023. Results: From 1999 to 2023, the national SLE-related AAMR declined from 1.03 to 0.73 per 100,000 (overall AAPC, -1.46%), while annual deaths increased slightly from 2,197 to 2,291. Joinpoint analysis identified a significant decline during 1999-2014, an increase during 2014-2021, and a sharp decline during 2021-2023. Women consistently had higher AAMRs than men. Adults aged ≥65 years had the highest mortality burden with little overall improvement. Black individuals maintained the highest AAMRs throughout, despite experiencing the steepest long-term decline. Geographically, the South, HHS Region 6, and Oklahoma remained high-burden areas. Nonmetropolitan areas showed smaller overall declines and steeper late-period increases. The underlying-cause-only sensitivity analysis also showed an AAMR decline from 0.59 to 0.29 per 100,000 (AAPC, -3.23%). Conclusion: U.S. SLE-related mortality declined overall from 1999 to 2023, but the absolute burden remained substantial and unequally distributed across demographic and geographic strata. Persistent excess mortality among women, older adults, Black individuals, and residents of high-burden areas highlights the need for more equitable translation of advances in lupus care into real-world survival gains.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.